tmem186 Antibody

What is TMEM186 and what cellular localization is associated with this protein?

TMEM186 (Transmembrane Protein 186) is a mitochondrial transmembrane protein expressed in human and mouse tissues. While specific functional characterization is still emerging in scientific literature, antibodies against TMEM186 are used to study its expression, localization, and potential roles in cellular processes. The protein is primarily localized to mitochondria, as indicated by background information provided by antibody manufacturers . Understanding TMEM186's subcellular localization is crucial for experimental design and interpretation of immunostaining results. Researchers typically use multiple techniques including immunofluorescence with mitochondrial markers to confirm localization patterns.

What types of TMEM186 antibodies are commercially available for research applications?

Several types of TMEM186 antibodies are available for research purposes, with variations in:

• Host species: Predominantly rabbit-derived polyclonal antibodies

• Clonality: Primarily polyclonal antibodies that recognize multiple epitopes

• Target epitopes: Different region-specific antibodies, including those targeting amino acids 124-213

• Conjugation status: Available as unconjugated or conjugated to reporter molecules like FITC, HRP, or biotin

• Reactivity: Most show reactivity against human TMEM186, with some cross-reacting with mouse TMEM186

These variations allow researchers to select antibodies appropriate for their specific experimental needs and detection systems.

What are the validated applications for TMEM186 antibodies?

TMEM186 antibodies have been validated for multiple experimental applications, including:

When selecting an antibody for a specific application, researchers should review the validation data provided by manufacturers and consider published literature where the antibody has been successfully employed.

What are the recommended storage and handling conditions for TMEM186 antibodies?

Proper storage and handling of TMEM186 antibodies are critical for maintaining their functionality:

• Storage temperature: Store at -20°C or -80°C for long-term preservation

• Avoid repeated freeze-thaw cycles: This can compromise antibody integrity and performance

• Buffer composition: Typically stored in a buffer containing preservatives (0.03% ProClin 300) and stabilizers (50% Glycerol, 0.01M PBS, pH 7.4)

• Safety considerations: Handle with appropriate precautions, especially for antibodies containing ProClin, which is classified as a hazardous substance

• Aliquoting: Prepare small working aliquots upon receipt to minimize freeze-thaw cycles

Following these storage and handling guidelines will help maintain antibody performance across experiments and extend shelf life.

How should researchers interpret TMEM186 antibody specificity data?

Interpreting antibody specificity is essential for generating reliable research data:

• Cross-reactivity profiles: Review the documented species cross-reactivity; most TMEM186 antibodies show reactivity against human proteins, with some cross-reacting with mouse TMEM186

• Epitope information: Consider the specific region recognized (e.g., amino acids 124-213) and how this may affect detection in different experimental contexts

• Validation methods: Evaluate the methods used to validate specificity, such as Western blotting with positive and negative controls

• Purification methods: Higher purity antibodies (e.g., >95% Protein G purified) generally offer better specificity

• Compare results from multiple antibodies: When possible, validate findings using antibodies targeting different epitopes of the same protein

Thorough evaluation of specificity data helps researchers select appropriate antibodies and correctly interpret experimental results.

What strategies can researchers employ to validate new TMEM186 antibodies for specific applications?

Comprehensive antibody validation requires multiple complementary approaches:

• Immunogen analysis: Compare the immunizing peptide sequence (e.g., 124-213AA of TMEM186) with homologous proteins to predict potential cross-reactivity

• Multiple detection methods: Validate using orthogonal techniques (Western blot, IHC, IF) to ensure consistent detection patterns

• Knockout/knockdown controls: Test antibody specificity in TMEM186-depleted or overexpressing systems

• Peptide competition assays: Pre-incubate antibody with immunizing peptide to confirm specific binding is blocked

• Cross-validation with multiple antibodies: Compare staining patterns from antibodies targeting different epitopes of TMEM186

• Correlation with mRNA expression: Compare protein detection with RNA expression data to establish consistency

This multi-faceted approach to validation, similar to that employed for TMEM106B antibodies in neurological research , ensures reliable detection and minimizes false-positive/negative results.

How can researchers optimize antigen retrieval methods for TMEM186 immunohistochemistry?

Effective antigen retrieval is crucial for successful TMEM186 detection in fixed tissues:

• Method selection: Evidence from similar transmembrane protein studies suggests formic acid (FA) treatment may be most effective for exposing TMEM186 epitopes

• Parameter optimization:

  • Duration: Test different treatment times (e.g., 1-5 minutes for FA)

  • Temperature: Evaluate heat-induced epitope retrieval at varying temperatures

  • pH conditions: Test buffers at different pH values to optimize epitope exposure

• Tissue-specific considerations: Different fixation methods and tissue types may require tailored retrieval protocols

• Sequential retrieval: For difficult antigens, consider combining multiple retrieval methods

• Antibody concentration optimization: Titrate antibody concentrations after establishing optimal retrieval conditions

When developing a new protocol, researchers should systematically test multiple conditions and document results quantitatively to determine optimal parameters.

What are the critical factors affecting signal amplification when using TMEM186 antibodies for low-abundance detection?

When detecting low-abundance TMEM186 protein, several amplification strategies can improve sensitivity:

• Signal amplification systems:

  • Tyramide Signal Amplification (TSA) can significantly enhance detection sensitivity

  • Polymer-based detection systems provide stronger signal with lower background

  • Biotin-streptavidin systems offer multi-layer amplification options

• Incubation optimizations:

  • Extended primary antibody incubation times (overnight at 4°C)

  • Optimized antibody concentration through systematic titration

• Background reduction strategies:

  • Appropriate blocking agents (based on host species)

  • Careful washing protocols to remove unbound antibody

  • Use of conjugated antibodies (e.g., FITC-conjugated) for direct detection when appropriate

• Data acquisition considerations:

  • Optimized microscope settings for low-abundance targets

  • Digital image enhancement without introducing artifacts

These approaches should be systematically tested and optimized for specific experimental conditions to maximize signal while maintaining specificity.

How can researchers troubleshoot non-specific binding or inconsistent staining patterns with TMEM186 antibodies?

Troubleshooting inconsistent TMEM186 antibody performance requires systematic analysis:

• Antibody quality issues:

  • Validate antibody integrity through simple dot blot assays

  • Test new antibody lots against previously validated lots

  • Ensure proper storage conditions have been maintained

• Protocol optimization:

  • Adjust blocking conditions (agent type, concentration, duration)

  • Modify antibody dilution and incubation parameters

  • Evaluate washing stringency and duration

• Sample-specific factors:

  • Assess tissue fixation methods and duration

  • Review sample preparation consistency

  • Consider antigen masking by interacting proteins

• Controls implementation:

  • Include positive and negative tissue controls

  • Implement secondary-only controls to assess background

  • Consider peptide competition controls to confirm specificity

• Cross-validation:

  • Compare results between different TMEM186 antibodies targeting distinct epitopes

  • Correlate with mRNA expression or other protein detection methods

Detailed documentation of troubleshooting steps creates a valuable resource for future experiments and protocol refinement.

How do post-translational modifications affect TMEM186 antibody epitope recognition?

Post-translational modifications (PTMs) can significantly impact TMEM186 antibody recognition:

• Common PTMs affecting epitope accessibility:

  • Phosphorylation of serine/threonine/tyrosine residues

  • Glycosylation of asparagine (N-linked) or serine/threonine (O-linked) residues

  • Proteolytic processing creating distinct protein fragments

• Antibody selection considerations:

  • Antibodies targeting amino acids 124-213 may recognize different forms depending on PTM status

  • Some antibodies may be PTM-specific or PTM-insensitive

  • Multiple antibodies recognizing different epitopes can help identify modification patterns

• Experimental strategies:

  • Enzymatic treatment to remove specific modifications before immunodetection

  • Combined use of modification-specific and total protein antibodies

  • Correlation with mass spectrometry data for comprehensive PTM analysis

• Interpretation guidelines:

  • Different molecular weight bands in Western blots may indicate modified forms

  • Altered subcellular localization may result from specific modifications

  • Changes in staining patterns under different cellular conditions may reflect dynamic modifications

Understanding the relationship between PTMs and epitope recognition enables more accurate interpretation of antibody-based detection results.

What are the recommended protocols for using TMEM186 antibodies in multiplexed immunofluorescence studies?

Multiplexed immunofluorescence with TMEM186 antibodies requires careful planning:

• Antibody compatibility assessment:

  • Select antibodies from different host species when possible

  • If using same-species antibodies, consider directly conjugated antibodies (e.g., TMEM186-FITC)

  • Test for cross-reactivity between secondary antibodies

• Sequential staining protocol:

  • Begin with lowest abundance target (often TMEM186)

  • Use tyramide signal amplification for signal preservation

  • Include thorough blocking between sequential antibody applications

• Controls for multiplexed staining:

  • Single-color controls to assess bleed-through

  • Secondary-only controls for each fluorophore

  • Absorption controls with immunizing peptides

• Co-localization analysis with cellular markers:

  • Combine TMEM186 antibodies with organelle markers (particularly mitochondrial)

  • Use cell-type-specific markers to assess expression patterns across populations

  • Similar to techniques used for TMEM106B studies , markers for neurons, astrocytes, oligodendrocytes, and other cell types

• Image acquisition considerations:

  • Sequential scanning to minimize spectral overlap

  • Consistent exposure settings across experimental groups

  • Resolution appropriate for subcellular localization studies

These methodological considerations enable reliable co-localization analysis and expression profiling across different cell types.

How should researchers design negative controls for validating TMEM186 antibody specificity?

Rigorous negative controls are essential for confirming TMEM186 antibody specificity:

• Genetic knockout/knockdown controls:

  • CRISPR/Cas9-mediated TMEM186 knockout cell lines

  • siRNA or shRNA knockdown of TMEM186

  • Comparison of staining between wild-type and TMEM186-depleted samples

• Peptide competition/absorption controls:

  • Pre-incubate antibody with excess immunizing peptide (e.g., 124-213AA)

  • Include gradient of peptide concentrations to demonstrate dose-dependent blocking

  • Use irrelevant peptides as negative control for absorption

• Secondary antibody-only controls:

  • Omit primary antibody while maintaining all other protocol steps

  • Assess background from secondary antibody binding

• Irrelevant primary antibody controls:

  • Use isotype-matched control antibody (rabbit IgG for polyclonal TMEM186 antibodies)

  • Apply at equivalent concentration to TMEM186 antibody

• Tissue/cell negativity controls:

  • Include samples with known absence of TMEM186 expression

  • Compare staining patterns across tissues with varying expression levels

Implementing these controls systematically provides compelling evidence for antibody specificity and enhances data reliability.

What statistical approaches are recommended for quantifying TMEM186 expression in immunohistochemistry studies?

Quantitative analysis of TMEM186 immunohistochemistry requires robust statistical methods:

• Image acquisition standardization:

  • Consistent staining protocol across all samples

  • Uniform image capture settings (exposure, gain, resolution)

  • Random field selection to avoid sampling bias

• Quantification approaches:

  • For DAB staining: H-score, Allred score, or percent positive cells

  • For fluorescence: Mean fluorescence intensity (MFI) or integrated density

  • Thresholding methods should be standardized and documented

• Statistical analysis recommendations:

  • Minimum sample size determination through power analysis

  • Normality testing before selecting parametric/non-parametric tests

  • Multiple comparison corrections for studies with numerous groups

  • Correlation analysis with other biomarkers or clinical parameters

• Reporting standards:

  • Transparent methodology description

  • Inclusion of representative images for each scoring category

  • Detailed statistical test information and exact p-values

  • Confidence intervals for key measurements

• Validation approaches:

  • Inter-observer concordance testing for manual scoring

  • Comparison between automated and manual quantification

  • Correlation with orthogonal measurements (e.g., Western blot, qPCR)

These statistical considerations ensure reproducible and reliable quantitative analysis of TMEM186 expression patterns.

How do antibodies targeting different epitopes of TMEM186 compare in their detection patterns?

Comparative analysis of different TMEM186 antibodies provides valuable insights:

• Epitope-dependent detection patterns:

  • Antibodies targeting amino acids 124-213 may yield different staining patterns than those targeting other regions

  • Accessibility of epitopes may vary depending on protein conformation, interactions, or modifications

  • Similar to findings with TMEM106B antibodies targeting different residues (188-211 vs. 239-250)

• Application-specific performance differences:

  • Some epitopes may be better preserved in fixed tissues

  • Denaturation-sensitive epitopes may work better in Western blot than IHC

  • Conformational epitopes may be superior for detecting native protein

• Interpretation guidelines:

  • Concordant results from multiple antibodies provide stronger evidence

  • Discrepancies may reveal biologically relevant protein variants or modifications

  • Consider epitope masking by protein-protein interactions

• Selection strategies for specific research questions:

  • Use multiple antibodies targeting different regions for comprehensive analysis

  • Select epitope-specific antibodies when studying protein processing or variants

  • Consider using antibody panels for complex experimental designs

This comparative approach enhances detection reliability and may reveal important biological information about TMEM186 structure and processing.

What criteria should researchers use when selecting between TMEM186 antibody formats for different applications?

Strategic selection between different TMEM186 antibody formats depends on experimental requirements:

Additional selection considerations include:

• Detection system compatibility:

  • Microscopy filter sets available for fluorescent conjugates

  • Enzyme substrates available for enzymatic conjugates

  • Secondary reagent availability for unconjugated antibodies

• Sensitivity requirements:

  • Signal amplification needs for low-abundance targets

  • Background concerns in specific tissues or applications

  • Direct vs. indirect detection trade-offs

• Multiplexing requirements:

  • Host species compatibility with other primary antibodies

  • Spectral overlap considerations for fluorescent conjugates

  • Sequential staining feasibility

Informed selection between formats optimizes detection sensitivity while minimizing technical complications.

How can researchers integrate TMEM186 antibody data with other molecular profiling approaches?

Integrative analysis enhances the value of TMEM186 antibody-generated data:

• Correlation with transcriptomic data:

  • Compare protein detection patterns with mRNA expression profiles

  • Analyze potential post-transcriptional regulation mechanisms

  • Identify discordance that may indicate regulated protein stability

• Integration with proteomic datasets:

  • Correlate antibody-based detection with mass spectrometry quantification

  • Compare PTM detection between antibody-based and MS-based methods

  • Use proteomics to identify TMEM186 interaction partners

• Functional genomics correlation:

  • Connect TMEM186 expression patterns with cellular phenotypes

  • Integrate with CRISPR screening or RNAi functional data

  • Correlate with metabolic profiles for mitochondrial function assessment

• Multi-omics data integration approaches:

  • Pathway analysis incorporating protein, transcript, and functional data

  • Network analysis to position TMEM186 in biological pathways

  • Machine learning to identify patterns across multi-modal datasets

• Visualization and analysis tools:

  • Hierarchical clustering of multi-parameter data

  • Dimension reduction techniques for pattern recognition

  • Interactive visualization platforms for exploratory analysis

This integrative approach provides a more comprehensive understanding of TMEM186 biology than any single method alone.

What emerging technologies may enhance TMEM186 antibody-based research?

Several emerging technologies show promise for advancing TMEM186 antibody applications:

• Advanced microscopy techniques:

  • Super-resolution microscopy for precise subcellular localization

  • Expansion microscopy for improved spatial resolution of mitochondrial proteins

  • Live-cell imaging with cell-permeable nanobodies or FLIP approaches

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) for single-cell protein quantification

  • Single-cell western blotting for heterogeneity assessment

  • Proximity ligation assays for protein interaction studies

• Spatial transcriptomics integration:

  • Combined antibody detection with spatial transcriptomics

  • Correlation of protein localization with local gene expression

  • Cell-type-specific expression pattern mapping

• Advanced antibody development:

  • Recombinant antibody engineering for improved specificity

  • Site-specific conjugation strategies for enhanced performance

  • Nanobody development for applications requiring small probes

• Computational advances:

  • Deep learning for automated image analysis

  • Integrative bioinformatics pipelines for multi-parameter data

  • Predictive modeling of protein-antibody interactions

Researchers should monitor these technological developments for opportunities to enhance TMEM186 detection sensitivity, specificity, and information content.

How should researchers approach contradictory findings when using different TMEM186 antibodies?

Reconciling contradictory results requires systematic investigation:

• Technical discrepancy assessment:

  • Review all methodological differences (fixation, retrieval, detection)

  • Evaluate antibody specifications (epitope, clonality, validation)

  • Assess potential lot-to-lot variability

• Biological interpretation considerations:

  • Epitope accessibility differences due to protein conformation

  • Post-translational modifications affecting specific epitopes

  • Presence of splice variants or processed forms

  • Protein interactions masking specific regions

• Validation approaches:

  • Side-by-side testing with standardized protocols

  • Genetic knockout/knockdown validation experiments

  • Orthogonal detection methods (mass spectrometry)

  • Combined use of multiple antibodies targeting different epitopes

• Reporting recommendations:

  • Transparent documentation of all contradictory findings

  • Detailed methodological reporting to facilitate replication

  • Clear antibody identification (catalog number, lot, epitope)

  • Discussion of potential biological explanations

• Resolution strategies:

  • Design experiments to distinguish between technical and biological causes

  • Generate hypotheses regarding protein processing or modifications

  • Develop isoform-specific detection strategies

This systematic approach transforms contradictory findings into research opportunities that may reveal important biological insights about TMEM186.